Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 254 entries
View as:

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02411435 Org: User:
Start: 07/31/15 End: 09/30/15 Due: 09/30/16

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

Phase: N/A Priority: Normal
NCT ID: NCT02478632 Org: User:
Start: 06/12/15 End: 08/17/18 Due: 08/17/19

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

Phase: N/A Priority: Normal
NCT ID: NCT04757974 Org: User:
Start: 03/05/21 End: 07/31/21 Due: 07/31/22

Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men

Phase: N/A Priority: Normal
NCT ID: NCT03310515 Org: User:
Start: 08/31/17 End: 12/31/18 Due: 12/31/19

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05418868 Org: User:
Start: 06/14/22 End: 11/02/27 Due: 11/02/28

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06368986 Org: User:
Start: 04/17/24 End: 10/02/24 Due: 10/02/25

GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study

Phase: N/A Priority: Normal
NCT ID: NCT00631592 Org: User:
Start: 02/29/08 End: 06/30/08 Due: 06/30/09

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

Phase: N/A Priority: Normal
NCT ID: NCT03446573 Org: User:
Start: 01/18/18 End: 05/03/22 Due: 05/03/23

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Phase: N/A Priority: Normal
NCT ID: NCT02076178 Org: User:
Start: 03/27/14 End: 02/23/16 Due: 02/23/17

HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University

Phase: N/A Priority: Normal
NCT ID: NCT01339416 Org: User:
Start: 03/31/09 End: 05/31/13 Due: 05/31/14

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01754116 Org: User:
Start: 01/31/13 End: 04/30/14 Due: 04/30/15

Kaiser Permanente HIV Cohort Study

Phase: N/A Priority: Normal
NCT ID: NCT01339403 Org: User:
Start: 02/28/09 End: 10/31/13 Due: 10/31/14

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Phase: N/A Priority: Normal
NCT ID: NCT03078556 Org: User:
Start: 03/27/17 End: 08/18/17 Due: 08/18/18

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Phase: N/A Priority: Normal
NCT ID: NCT02386098 Org: User:
Start: 07/08/15 End: 06/07/17 Due: 06/07/18

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02227238 Org: User:
Start: 12/11/14 End: 02/14/22 Due: 02/14/23

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Phase: N/A Priority: Normal
NCT ID: NCT02105987 Org: User:
Start: 04/30/14 End: 12/31/15 Due: 12/31/16

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02467335 Org: User:
Start: 01/29/15 End: 10/03/15 Due: 10/03/16

GW873140 In Combination With Kaletra In HIV Infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00102778 Org: User:
Start: 12/31/04 End: 09/30/07 Due: 09/30/08

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

Phase: N/A Priority: Normal
NCT ID: NCT05374525 Org: User:
Start: 05/18/22 End: 08/08/24 Due: 08/08/25

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT04019873 Org: User:
Start: 11/18/19 End: 12/05/23 Due: 12/05/24

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01332565 Org: User:
Start: 04/30/11 End: 06/30/11 Due: 06/30/12

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

Phase: N/A Priority: Normal
NCT ID: NCT03314064 Org: User:
Start: 12/08/16 End: 10/01/18 Due: 10/01/19

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Phase: N/A Priority: Normal
NCT ID: NCT01910402 Org: User:
Start: 08/22/13 End: 08/18/22 Due: 08/18/23

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT06310616 Org: User:
Start: 03/06/24 End: 08/15/24 Due: 08/15/25

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00098748 Org: User:
Start: 11/30/04 End: 04/30/09 Due: 04/30/10